| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 91 | 2023 | 1180 | 10.290 |
Why?
|
| Parkinsonian Disorders | 24 | 2023 | 170 | 9.660 |
Why?
|
| Brain | 59 | 2023 | 1241 | 7.330 |
Why?
|
| Alzheimer Disease | 69 | 2023 | 1414 | 6.820 |
Why?
|
| Aged, 80 and over | 178 | 2023 | 3865 | 6.410 |
Why?
|
| Motor Activity | 29 | 2021 | 274 | 6.230 |
Why?
|
| Cognition | 46 | 2023 | 1026 | 5.480 |
Why?
|
| Cognitive Dysfunction | 35 | 2023 | 806 | 5.480 |
Why?
|
| Aged | 185 | 2023 | 7660 | 5.160 |
Why?
|
| Disabled Persons | 16 | 2023 | 89 | 4.580 |
Why?
|
| Parkinson Disease | 26 | 2023 | 595 | 4.420 |
Why?
|
| Male | 199 | 2023 | 12659 | 4.340 |
Why?
|
| Female | 195 | 2023 | 13142 | 4.120 |
Why?
|
| Humans | 252 | 2023 | 23187 | 3.990 |
Why?
|
| Cognition Disorders | 39 | 2021 | 726 | 3.440 |
Why?
|
| Independent Living | 16 | 2023 | 240 | 3.290 |
Why?
|
| Exercise | 15 | 2023 | 404 | 3.200 |
Why?
|
| Mobility Limitation | 11 | 2021 | 78 | 3.160 |
Why?
|
| Dementia | 23 | 2023 | 416 | 2.960 |
Why?
|
| Longitudinal Studies | 56 | 2023 | 1106 | 2.800 |
Why?
|
| Activities of Daily Living | 27 | 2023 | 369 | 2.690 |
Why?
|
| Intracranial Arteriosclerosis | 5 | 2022 | 41 | 2.580 |
Why?
|
| Gait | 14 | 2023 | 384 | 2.570 |
Why?
|
| Geriatric Assessment | 17 | 2021 | 171 | 2.460 |
Why?
|
| Arteriolosclerosis | 7 | 2023 | 61 | 2.450 |
Why?
|
| Muscle Strength | 15 | 2021 | 99 | 2.290 |
Why?
|
| Frail Elderly | 8 | 2021 | 37 | 2.270 |
Why?
|
| Cohort Studies | 59 | 2021 | 1467 | 2.260 |
Why?
|
| Cerebrovascular Disorders | 6 | 2023 | 104 | 2.090 |
Why?
|
| Risk Factors | 46 | 2023 | 2020 | 1.890 |
Why?
|
| Spinal Cord | 5 | 2022 | 74 | 1.870 |
Why?
|
| Residence Characteristics | 13 | 2021 | 179 | 1.810 |
Why?
|
| Disability Evaluation | 18 | 2020 | 225 | 1.690 |
Why?
|
| Wearable Electronic Devices | 6 | 2021 | 41 | 1.690 |
Why?
|
| Proportional Hazards Models | 24 | 2021 | 279 | 1.650 |
Why?
|
| Neuropsychological Tests | 37 | 2023 | 917 | 1.640 |
Why?
|
| Motor Skills | 6 | 2021 | 38 | 1.620 |
Why?
|
| Disease Progression | 19 | 2021 | 547 | 1.600 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 43 | 1.540 |
Why?
|
| Brain Diseases | 4 | 2020 | 56 | 1.530 |
Why?
|
| Memory | 15 | 2019 | 225 | 1.520 |
Why?
|
| Hand Strength | 7 | 2023 | 49 | 1.520 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 1430 | 1.490 |
Why?
|
| Sarcopenia | 3 | 2021 | 25 | 1.490 |
Why?
|
| Motor Disorders | 4 | 2023 | 18 | 1.440 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2021 | 277 | 1.420 |
Why?
|
| Walking Speed | 3 | 2021 | 35 | 1.410 |
Why?
|
| Cerebral Amyloid Angiopathy | 5 | 2021 | 96 | 1.360 |
Why?
|
| Lewy Body Disease | 7 | 2021 | 74 | 1.310 |
Why?
|
| White Matter | 5 | 2021 | 113 | 1.310 |
Why?
|
| Sleep Deprivation | 6 | 2022 | 35 | 1.280 |
Why?
|
| Prospective Studies | 26 | 2023 | 1512 | 1.280 |
Why?
|
| Psychomotor Performance | 7 | 2021 | 165 | 1.270 |
Why?
|
| Neurons | 10 | 2022 | 273 | 1.230 |
Why?
|
| Autopsy | 16 | 2022 | 260 | 1.220 |
Why?
|
| Movement Disorders | 5 | 2021 | 57 | 1.200 |
Why?
|
| Frailty | 4 | 2023 | 22 | 1.180 |
Why?
|
| Postural Balance | 7 | 2021 | 112 | 1.110 |
Why?
|
| Lewy Bodies | 15 | 2023 | 151 | 1.090 |
Why?
|
| Incidence | 15 | 2021 | 633 | 1.090 |
Why?
|
| Muscle Weakness | 5 | 2021 | 27 | 1.070 |
Why?
|
| Nervous System Diseases | 4 | 2017 | 101 | 1.030 |
Why?
|
| Movement | 4 | 2020 | 106 | 1.030 |
Why?
|
| Urinary Incontinence | 2 | 2017 | 21 | 0.970 |
Why?
|
| Muscle, Skeletal | 8 | 2021 | 341 | 0.970 |
Why?
|
| Accelerometry | 5 | 2021 | 83 | 0.940 |
Why?
|
| Amyloid beta-Peptides | 8 | 2023 | 210 | 0.930 |
Why?
|
| Genome-Wide Association Study | 15 | 2021 | 160 | 0.930 |
Why?
|
| Prefrontal Cortex | 5 | 2023 | 107 | 0.910 |
Why?
|
| Cerebral Infarction | 6 | 2016 | 113 | 0.910 |
Why?
|
| Memory, Episodic | 5 | 2023 | 81 | 0.890 |
Why?
|
| Atherosclerosis | 2 | 2023 | 47 | 0.890 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 132 | 0.890 |
Why?
|
| Walking | 9 | 2023 | 235 | 0.880 |
Why?
|
| Age Factors | 20 | 2021 | 651 | 0.870 |
Why?
|
| Apolipoprotein E4 | 9 | 2020 | 184 | 0.860 |
Why?
|
| Actigraphy | 17 | 2022 | 81 | 0.830 |
Why?
|
| Neuropeptides | 1 | 2023 | 22 | 0.820 |
Why?
|
| Cognitive Aging | 2 | 2021 | 64 | 0.820 |
Why?
|
| Body Mass Index | 7 | 2023 | 381 | 0.810 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 20 | 0.810 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 87 | 0.800 |
Why?
|
| Substantia Nigra | 5 | 2021 | 102 | 0.790 |
Why?
|
| Sleep | 12 | 2022 | 270 | 0.780 |
Why?
|
| Glycation End Products, Advanced | 2 | 2022 | 6 | 0.770 |
Why?
|
| Cerebrum | 1 | 2023 | 6 | 0.770 |
Why?
|
| Middle Aged | 48 | 2021 | 7981 | 0.740 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2021 | 875 | 0.690 |
Why?
|
| Brain Infarction | 6 | 2020 | 63 | 0.670 |
Why?
|
| Peptides | 1 | 2021 | 89 | 0.660 |
Why?
|
| Motor Neurons | 3 | 2018 | 15 | 0.660 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 2 | 2019 | 21 | 0.640 |
Why?
|
| Mortality | 4 | 2020 | 76 | 0.640 |
Why?
|
| Range of Motion, Articular | 2 | 2019 | 565 | 0.630 |
Why?
|
| Gait Disorders, Neurologic | 7 | 2021 | 120 | 0.630 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2021 | 36 | 0.630 |
Why?
|
| Chicago | 14 | 2021 | 847 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2021 | 176 | 0.620 |
Why?
|
| Longevity | 4 | 2014 | 19 | 0.620 |
Why?
|
| Circadian Rhythm | 7 | 2023 | 213 | 0.620 |
Why?
|
| Lung | 3 | 2021 | 139 | 0.600 |
Why?
|
| Apolipoproteins E | 4 | 2018 | 160 | 0.600 |
Why?
|
| Linear Models | 9 | 2023 | 202 | 0.600 |
Why?
|
| Executive Function | 3 | 2022 | 94 | 0.570 |
Why?
|
| Olfaction Disorders | 5 | 2021 | 38 | 0.540 |
Why?
|
| Proteome | 3 | 2023 | 23 | 0.530 |
Why?
|
| Microvessels | 1 | 2017 | 12 | 0.530 |
Why?
|
| United States | 13 | 2021 | 1803 | 0.530 |
Why?
|
| Phenotype | 9 | 2023 | 260 | 0.530 |
Why?
|
| Time Factors | 14 | 2021 | 1264 | 0.520 |
Why?
|
| Proteomics | 3 | 2023 | 61 | 0.510 |
Why?
|
| Locus Coeruleus | 3 | 2013 | 16 | 0.500 |
Why?
|
| alpha-Synuclein | 4 | 2018 | 103 | 0.500 |
Why?
|
| Regression Analysis | 6 | 2020 | 216 | 0.490 |
Why?
|
| Sex Factors | 10 | 2020 | 399 | 0.490 |
Why?
|
| tau Proteins | 5 | 2023 | 153 | 0.480 |
Why?
|
| Motor Skills Disorders | 2 | 2018 | 14 | 0.470 |
Why?
|
| Comorbidity | 6 | 2021 | 429 | 0.460 |
Why?
|
| Electromyography | 6 | 2001 | 67 | 0.460 |
Why?
|
| Visceral Afferents | 1 | 2015 | 3 | 0.460 |
Why?
|
| Sleep Wake Disorders | 5 | 2019 | 110 | 0.460 |
Why?
|
| Genotype | 10 | 2018 | 265 | 0.460 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2015 | 7 | 0.460 |
Why?
|
| Body Composition | 3 | 2019 | 66 | 0.460 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 804 | 0.450 |
Why?
|
| Multiple System Atrophy | 1 | 2015 | 26 | 0.440 |
Why?
|
| Knee Joint | 1 | 2019 | 572 | 0.440 |
Why?
|
| Self Report | 5 | 2021 | 202 | 0.430 |
Why?
|
| Harm Reduction | 1 | 2014 | 5 | 0.420 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 295 | 0.420 |
Why?
|
| Neuroimaging | 3 | 2021 | 105 | 0.410 |
Why?
|
| Locomotion | 1 | 2014 | 21 | 0.410 |
Why?
|
| Vascular Diseases | 2 | 2013 | 34 | 0.400 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 30 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 150 | 0.390 |
Why?
|
| Logistic Models | 8 | 2020 | 357 | 0.390 |
Why?
|
| Consensus | 1 | 2013 | 81 | 0.390 |
Why?
|
| Neurodegenerative Diseases | 3 | 2021 | 98 | 0.390 |
Why?
|
| Physical Fitness | 3 | 2009 | 48 | 0.390 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 9 | 0.390 |
Why?
|
| Hippocampus | 4 | 2019 | 200 | 0.390 |
Why?
|
| DNA Methylation | 3 | 2021 | 129 | 0.380 |
Why?
|
| Quantitative Trait Loci | 5 | 2020 | 26 | 0.380 |
Why?
|
| Kidney | 3 | 2010 | 142 | 0.380 |
Why?
|
| Gene Expression | 5 | 2020 | 180 | 0.370 |
Why?
|
| Sex Characteristics | 4 | 2018 | 91 | 0.360 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 93 | 0.360 |
Why?
|
| Respiratory Muscles | 2 | 2008 | 13 | 0.360 |
Why?
|
| Survival Rate | 2 | 2012 | 320 | 0.360 |
Why?
|
| Fatigue | 2 | 2009 | 47 | 0.350 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 164 | 0.350 |
Why?
|
| Neurofibrillary Tangles | 4 | 2023 | 121 | 0.350 |
Why?
|
| Leg | 3 | 2008 | 40 | 0.350 |
Why?
|
| Loneliness | 2 | 2014 | 45 | 0.350 |
Why?
|
| Olfactory Bulb | 2 | 2023 | 12 | 0.350 |
Why?
|
| Risk Assessment | 7 | 2021 | 550 | 0.340 |
Why?
|
| DNA-Binding Proteins | 5 | 2023 | 231 | 0.340 |
Why?
|
| Microglia | 3 | 2021 | 108 | 0.340 |
Why?
|
| Pain | 2 | 2010 | 332 | 0.340 |
Why?
|
| Myasthenia Gravis | 2 | 2006 | 32 | 0.330 |
Why?
|
| Educational Status | 6 | 2015 | 223 | 0.320 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2015 | 273 | 0.320 |
Why?
|
| Illinois | 4 | 2020 | 224 | 0.310 |
Why?
|
| Diet | 2 | 2022 | 181 | 0.310 |
Why?
|
| Somatosensory Disorders | 1 | 2009 | 10 | 0.300 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 21 | 0.300 |
Why?
|
| Social Adjustment | 1 | 2009 | 21 | 0.300 |
Why?
|
| Vibration | 1 | 2009 | 24 | 0.300 |
Why?
|
| Health Status | 2 | 2012 | 204 | 0.290 |
Why?
|
| Neocortex | 3 | 2019 | 23 | 0.290 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 36 | 0.290 |
Why?
|
| Polyneuropathies | 1 | 2008 | 1 | 0.290 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 17 | 0.290 |
Why?
|
| Genome, Human | 2 | 2020 | 34 | 0.280 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 778 | 0.280 |
Why?
|
| Isometric Contraction | 3 | 2007 | 8 | 0.280 |
Why?
|
| ROC Curve | 3 | 2022 | 122 | 0.280 |
Why?
|
| Rest | 4 | 2023 | 28 | 0.270 |
Why?
|
| Synapses | 2 | 2021 | 23 | 0.270 |
Why?
|
| Risk | 9 | 2020 | 166 | 0.270 |
Why?
|
| Adult | 21 | 2019 | 6959 | 0.270 |
Why?
|
| Diet, Mediterranean | 2 | 2019 | 72 | 0.270 |
Why?
|
| Tremor | 3 | 2021 | 98 | 0.270 |
Why?
|
| Causality | 2 | 2021 | 44 | 0.260 |
Why?
|
| Models, Statistical | 2 | 2020 | 116 | 0.250 |
Why?
|
| Thymoma | 1 | 2006 | 7 | 0.250 |
Why?
|
| Thymus Neoplasms | 1 | 2006 | 13 | 0.250 |
Why?
|
| Life Style | 3 | 2020 | 167 | 0.240 |
Why?
|
| Myositis | 1 | 2006 | 16 | 0.240 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2019 | 20 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2007 | 84 | 0.240 |
Why?
|
| Eosinophilia | 1 | 2006 | 36 | 0.240 |
Why?
|
| Dystonia | 2 | 1998 | 11 | 0.240 |
Why?
|
| Goals | 3 | 2010 | 35 | 0.230 |
Why?
|
| Cachexia | 1 | 2005 | 10 | 0.230 |
Why?
|
| Memory Disorders | 5 | 2015 | 116 | 0.230 |
Why?
|
| Alleles | 7 | 2018 | 172 | 0.230 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 442 | 0.220 |
Why?
|
| Animals | 7 | 2022 | 3271 | 0.220 |
Why?
|
| Postmortem Changes | 2 | 2016 | 22 | 0.220 |
Why?
|
| Self-Assessment | 2 | 2021 | 20 | 0.210 |
Why?
|
| Analysis of Variance | 3 | 2021 | 228 | 0.210 |
Why?
|
| Electric Impedance | 2 | 2021 | 24 | 0.210 |
Why?
|
| Physical Therapy Modalities | 2 | 2022 | 58 | 0.210 |
Why?
|
| GPI-Linked Proteins | 1 | 2023 | 16 | 0.210 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2021 | 7 | 0.210 |
Why?
|
| RNA, Messenger | 4 | 2017 | 283 | 0.210 |
Why?
|
| Transcriptome | 2 | 2021 | 54 | 0.210 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 10 | 0.200 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 226 | 0.200 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 60 | 0.200 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 4 | 0.200 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 4 | 0.200 |
Why?
|
| Fitness Trackers | 2 | 2021 | 10 | 0.200 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 109 | 0.190 |
Why?
|
| Genetic Association Studies | 4 | 2016 | 58 | 0.190 |
Why?
|
| Decision Making | 3 | 2013 | 179 | 0.190 |
Why?
|
| Triglycerides | 1 | 2022 | 54 | 0.190 |
Why?
|
| Prognosis | 4 | 2019 | 730 | 0.190 |
Why?
|
| Cholesterol | 1 | 2022 | 57 | 0.190 |
Why?
|
| Glycopeptides | 1 | 2022 | 2 | 0.190 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 354 | 0.190 |
Why?
|
| Cognitive Reserve | 1 | 2022 | 24 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 5 | 2023 | 25 | 0.180 |
Why?
|
| Interpersonal Relations | 2 | 2014 | 91 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2020 | 171 | 0.180 |
Why?
|
| Individuality | 1 | 2022 | 15 | 0.180 |
Why?
|
| Eating | 1 | 2022 | 47 | 0.180 |
Why?
|
| Reaction Time | 3 | 2016 | 81 | 0.180 |
Why?
|
| Cell Count | 4 | 2015 | 72 | 0.170 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 102 | 0.170 |
Why?
|
| Proteins | 2 | 2020 | 51 | 0.170 |
Why?
|
| Genetic Variation | 3 | 2016 | 71 | 0.170 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 10 | 0.170 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2021 | 4 | 0.170 |
Why?
|
| Amygdala | 1 | 2021 | 35 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 2021 | 42 | 0.170 |
Why?
|
| Hypertension | 3 | 2020 | 169 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 49 | 0.170 |
Why?
|
| Apolipoprotein C-I | 1 | 2020 | 1 | 0.170 |
Why?
|
| Ribonucleases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Sex Distribution | 2 | 2012 | 66 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2021 | 89 | 0.160 |
Why?
|
| Chronobiology Disorders | 1 | 2020 | 13 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 3 | 2021 | 117 | 0.160 |
Why?
|
| Reference Values | 3 | 2012 | 169 | 0.160 |
Why?
|
| Torticollis | 2 | 1998 | 8 | 0.160 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2020 | 45 | 0.160 |
Why?
|
| Personality | 2 | 2013 | 42 | 0.160 |
Why?
|
| Antioxidants | 1 | 2020 | 56 | 0.160 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 12 | 0.150 |
Why?
|
| Histones | 1 | 2019 | 28 | 0.150 |
Why?
|
| Heart Failure | 1 | 2021 | 141 | 0.150 |
Why?
|
| Temporal Lobe | 2 | 2017 | 58 | 0.150 |
Why?
|
| Infarction | 2 | 2023 | 21 | 0.150 |
Why?
|
| Neuropathology | 2 | 2019 | 63 | 0.150 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2019 | 26 | 0.150 |
Why?
|
| Body Fluid Compartments | 1 | 2019 | 4 | 0.150 |
Why?
|
| Social Environment | 2 | 2011 | 71 | 0.150 |
Why?
|
| Risk-Taking | 2 | 2011 | 28 | 0.150 |
Why?
|
| Young Adult | 5 | 2019 | 1657 | 0.140 |
Why?
|
| Cause of Death | 2 | 2009 | 56 | 0.140 |
Why?
|
| Depression | 4 | 2016 | 383 | 0.140 |
Why?
|
| Seasons | 1 | 2018 | 19 | 0.140 |
Why?
|
| Suprachiasmatic Nucleus | 2 | 2015 | 10 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2016 | 227 | 0.140 |
Why?
|
| Neck Muscles | 1 | 1998 | 6 | 0.140 |
Why?
|
| Head Movements | 1 | 1998 | 6 | 0.140 |
Why?
|
| Adipose Tissue | 1 | 2019 | 73 | 0.140 |
Why?
|
| Quality of Life | 3 | 2012 | 564 | 0.140 |
Why?
|
| Prodromal Symptoms | 1 | 2018 | 17 | 0.140 |
Why?
|
| Haptoglobins | 1 | 2017 | 2 | 0.130 |
Why?
|
| Corpus Striatum | 1 | 2018 | 63 | 0.130 |
Why?
|
| Pseudogenes | 1 | 2017 | 1 | 0.130 |
Why?
|
| Thinness | 1 | 2017 | 1 | 0.130 |
Why?
|
| Hypokinesia | 3 | 2014 | 16 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 338 | 0.130 |
Why?
|
| Anterior Horn Cells | 1 | 2017 | 1 | 0.130 |
Why?
|
| RNA | 1 | 2017 | 28 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 35 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2017 | 38 | 0.130 |
Why?
|
| HIV Infections | 1 | 2021 | 439 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2017 | 104 | 0.130 |
Why?
|
| Energy Metabolism | 2 | 2019 | 42 | 0.130 |
Why?
|
| Lumbosacral Region | 1 | 2017 | 51 | 0.130 |
Why?
|
| Memory, Short-Term | 4 | 2021 | 81 | 0.120 |
Why?
|
| Botulinum Toxins | 2 | 1993 | 8 | 0.120 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 44 | 0.120 |
Why?
|
| Haplotypes | 1 | 2016 | 43 | 0.120 |
Why?
|
| Early Diagnosis | 2 | 2014 | 51 | 0.120 |
Why?
|
| Muscle Rigidity | 2 | 2014 | 13 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2020 | 485 | 0.120 |
Why?
|
| Cerebral Arteries | 1 | 2016 | 21 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 3 | 2014 | 63 | 0.120 |
Why?
|
| Period Circadian Proteins | 2 | 2013 | 11 | 0.120 |
Why?
|
| Intention | 3 | 2010 | 16 | 0.120 |
Why?
|
| Homes for the Aged | 1 | 2015 | 7 | 0.120 |
Why?
|
| Body Size | 1 | 2015 | 6 | 0.120 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Adiposity | 1 | 2016 | 42 | 0.120 |
Why?
|
| Receptors, Complement 3b | 2 | 2016 | 8 | 0.120 |
Why?
|
| Biomarkers | 4 | 2021 | 486 | 0.120 |
Why?
|
| Gray Matter | 1 | 2016 | 43 | 0.120 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2015 | 2 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 42 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2016 | 57 | 0.110 |
Why?
|
| Sacrum | 1 | 2015 | 21 | 0.110 |
Why?
|
| Fractals | 3 | 2019 | 18 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 31 | 0.110 |
Why?
|
| Preoptic Area | 1 | 2014 | 5 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 55 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 526 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 18 | 0.110 |
Why?
|
| Sensation Disorders | 1 | 2014 | 9 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 95 | 0.110 |
Why?
|
| Retirement | 2 | 2011 | 9 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2014 | 215 | 0.110 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 88 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2014 | 31 | 0.100 |
Why?
|
| Mesencephalon | 1 | 2013 | 21 | 0.100 |
Why?
|
| Telemetry | 1 | 2013 | 7 | 0.100 |
Why?
|
| Financial Management | 1 | 2013 | 18 | 0.100 |
Why?
|
| Dyssomnias | 1 | 2013 | 5 | 0.100 |
Why?
|
| Muscles | 1 | 1993 | 56 | 0.100 |
Why?
|
| CLOCK Proteins | 1 | 2013 | 11 | 0.100 |
Why?
|
| Brain Stem | 1 | 2013 | 16 | 0.100 |
Why?
|
| Synucleins | 1 | 2013 | 5 | 0.100 |
Why?
|
| Social Behavior | 2 | 2011 | 54 | 0.100 |
Why?
|
| Gene Frequency | 1 | 2013 | 42 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2013 | 13 | 0.100 |
Why?
|
| Health Surveys | 1 | 2013 | 78 | 0.100 |
Why?
|
| Neuroticism | 1 | 2013 | 23 | 0.100 |
Why?
|
| Anxiety | 1 | 2013 | 143 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 13 | 0.100 |
Why?
|
| Glucosylceramidase | 1 | 2012 | 13 | 0.090 |
Why?
|
| Time Perception | 1 | 2012 | 4 | 0.090 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 19 | 0.090 |
Why?
|
| Amyloid | 1 | 2012 | 38 | 0.090 |
Why?
|
| Child Abuse | 1 | 2012 | 29 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 48 | 0.090 |
Why?
|
| Neuromuscular Junction | 1 | 1992 | 7 | 0.090 |
Why?
|
| Atrophy | 2 | 2009 | 68 | 0.090 |
Why?
|
| Emotions | 1 | 2012 | 69 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2012 | 40 | 0.090 |
Why?
|
| Data Collection | 2 | 2010 | 83 | 0.090 |
Why?
|
| Health Literacy | 1 | 2013 | 87 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 77 | 0.090 |
Why?
|
| Algorithms | 3 | 2021 | 305 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2011 | 26 | 0.090 |
Why?
|
| Wakefulness | 1 | 2011 | 68 | 0.090 |
Why?
|
| Urban Population | 2 | 2010 | 131 | 0.090 |
Why?
|
| Mutation | 1 | 2012 | 330 | 0.080 |
Why?
|
| Chronic Pain | 1 | 2012 | 127 | 0.080 |
Why?
|
| Social Participation | 1 | 2011 | 11 | 0.080 |
Why?
|
| Environmental Health | 1 | 2010 | 7 | 0.080 |
Why?
|
| Plaque, Amyloid | 1 | 2011 | 90 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 35 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 106 | 0.080 |
Why?
|
| Phobic Disorders | 1 | 2010 | 65 | 0.080 |
Why?
|
| Potassium | 1 | 2010 | 59 | 0.080 |
Why?
|
| Image Enhancement | 1 | 1990 | 42 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 26 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1990 | 32 | 0.080 |
Why?
|
| Neurologic Examination | 2 | 2007 | 82 | 0.080 |
Why?
|
| Microcirculation | 1 | 2009 | 26 | 0.080 |
Why?
|
| Mechanoreceptors | 1 | 2009 | 6 | 0.080 |
Why?
|
| Proprioception | 1 | 2009 | 18 | 0.070 |
Why?
|
| Age Distribution | 1 | 2009 | 69 | 0.070 |
Why?
|
| Research Design | 2 | 2012 | 162 | 0.070 |
Why?
|
| Sural Nerve | 1 | 2008 | 4 | 0.070 |
Why?
|
| Peroneal Nerve | 1 | 2008 | 5 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2008 | 46 | 0.070 |
Why?
|
| Inflammation | 1 | 2010 | 230 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2008 | 95 | 0.070 |
Why?
|
| Joints | 1 | 2009 | 67 | 0.070 |
Why?
|
| Ergometry | 1 | 2008 | 2 | 0.070 |
Why?
|
| Foot | 1 | 2008 | 40 | 0.070 |
Why?
|
| Extremities | 1 | 2008 | 24 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2021 | 140 | 0.070 |
Why?
|
| ADAMTS Proteins | 2 | 2019 | 3 | 0.070 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2019 | 3 | 0.070 |
Why?
|
| Versicans | 2 | 2019 | 6 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2014 | 2993 | 0.070 |
Why?
|
| Action Potentials | 1 | 2008 | 83 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2019 | 40 | 0.070 |
Why?
|
| Catholicism | 1 | 2007 | 13 | 0.070 |
Why?
|
| Visual Perception | 1 | 2007 | 21 | 0.070 |
Why?
|
| Bromocriptine | 1 | 1987 | 3 | 0.070 |
Why?
|
| Myoclonus | 1 | 1987 | 7 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2007 | 33 | 0.070 |
Why?
|
| Dementia, Vascular | 1 | 2007 | 36 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2017 | 16 | 0.060 |
Why?
|
| Personal Space | 1 | 2007 | 5 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 30 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 107 | 0.060 |
Why?
|
| Clergy | 1 | 2007 | 72 | 0.060 |
Why?
|
| Heterozygote | 2 | 2018 | 90 | 0.060 |
Why?
|
| Pyridostigmine Bromide | 1 | 2006 | 2 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2006 | 12 | 0.060 |
Why?
|
| Eye Movements | 1 | 2006 | 10 | 0.060 |
Why?
|
| Neural Conduction | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 13 | 0.060 |
Why?
|
| Peritonitis | 1 | 2006 | 17 | 0.060 |
Why?
|
| Ophthalmoplegia | 1 | 1986 | 2 | 0.060 |
Why?
|
| Quadriplegia | 1 | 1986 | 8 | 0.060 |
Why?
|
| Prednisone | 1 | 2006 | 64 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2020 | 124 | 0.060 |
Why?
|
| Diagnosis | 2 | 2016 | 18 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 67 | 0.060 |
Why?
|
| Biotechnology | 1 | 2005 | 1 | 0.060 |
Why?
|
| Motion Therapy, Continuous Passive | 1 | 2005 | 5 | 0.060 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2005 | 9 | 0.060 |
Why?
|
| Rehabilitation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Medical Informatics | 1 | 2005 | 8 | 0.060 |
Why?
|
| Robotics | 1 | 2005 | 20 | 0.060 |
Why?
|
| Body Weight | 1 | 2005 | 129 | 0.060 |
Why?
|
| Sialorrhea | 1 | 2005 | 1 | 0.060 |
Why?
|
| Neuromuscular Agents | 1 | 2005 | 3 | 0.060 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2005 | 6 | 0.060 |
Why?
|
| Stiff-Person Syndrome | 1 | 2004 | 1 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2004 | 2 | 0.050 |
Why?
|
| Elbow | 2 | 2001 | 40 | 0.050 |
Why?
|
| Adolescent | 3 | 2019 | 1884 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2022 | 5 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 9 | 0.050 |
Why?
|
| Wrist | 1 | 2022 | 16 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2022 | 3 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 5 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 14 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 47 | 0.050 |
Why?
|
| Stem Cells | 1 | 2022 | 34 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 59 | 0.050 |
Why?
|
| Synaptotagmins | 1 | 2021 | 2 | 0.040 |
Why?
|
| Synapsins | 1 | 2021 | 4 | 0.040 |
Why?
|
| Synaptophysin | 1 | 2021 | 7 | 0.040 |
Why?
|
| Qa-SNARE Proteins | 1 | 2021 | 5 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 37 | 0.040 |
Why?
|
| Stroke | 2 | 2016 | 243 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2021 | 35 | 0.040 |
Why?
|
| Boston | 1 | 2021 | 13 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 11 | 0.040 |
Why?
|
| Astrocytes | 1 | 2022 | 126 | 0.040 |
Why?
|
| CpG Islands | 1 | 2021 | 43 | 0.040 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 9 | 0.040 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2021 | 1 | 0.040 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2021 | 6 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2021 | 94 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 51 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 1 | 2020 | 2 | 0.040 |
Why?
|
| Israel | 1 | 2020 | 11 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 32 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 8 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2020 | 30 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 32 | 0.040 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 5 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 46 | 0.040 |
Why?
|
| Carotenoids | 1 | 2020 | 15 | 0.040 |
Why?
|
| Insect Proteins | 1 | 2000 | 1 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 9 | 0.040 |
Why?
|
| Drosophila melanogaster | 2 | 2016 | 9 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2020 | 31 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 101 | 0.040 |
Why?
|
| Vitamin E | 1 | 2020 | 38 | 0.040 |
Why?
|
| Acetylation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2020 | 173 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 226 | 0.040 |
Why?
|
| Synaptic Vesicles | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 85 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2019 | 2 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 19 | 0.040 |
Why?
|
| Axons | 1 | 2019 | 24 | 0.040 |
Why?
|
| Odorants | 2 | 2009 | 15 | 0.040 |
Why?
|
| Mitochondria | 1 | 2019 | 55 | 0.040 |
Why?
|
| Psychometrics | 2 | 2010 | 184 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2018 | 17 | 0.040 |
Why?
|
| Smoking | 1 | 2020 | 163 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 1037 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 10 | 0.040 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2009 | 13 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 86 | 0.040 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 30 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 27 | 0.030 |
Why?
|
| Religious Personnel | 1 | 2018 | 9 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 35 | 0.030 |
Why?
|
| Sclerosis | 1 | 2017 | 54 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2017 | 1 | 0.030 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2017 | 2 | 0.030 |
Why?
|
| Child | 3 | 2012 | 1160 | 0.030 |
Why?
|
| Neuronal Tract-Tracers | 1 | 2017 | 1 | 0.030 |
Why?
|
| Neuroanatomical Tract-Tracing Techniques | 1 | 2017 | 1 | 0.030 |
Why?
|
| Fixatives | 1 | 2017 | 5 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2017 | 5 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2017 | 7 | 0.030 |
Why?
|
| Species Specificity | 1 | 2017 | 34 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2017 | 15 | 0.030 |
Why?
|
| Cats | 1 | 2017 | 28 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2017 | 56 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 47 | 0.030 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2007 | 73 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 14 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 3 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 17 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 37 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 10 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 19 | 0.030 |
Why?
|
| Arterioles | 1 | 2016 | 11 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 32 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 52 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 40 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 363 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 139 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2015 | 12 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 24 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 72 | 0.030 |
Why?
|
| Awareness | 1 | 2015 | 40 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 15 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 47 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2014 | 2 | 0.030 |
Why?
|
| Introns | 1 | 2014 | 13 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 36 | 0.030 |
Why?
|
| Receptors, Kainic Acid | 1 | 2014 | 1 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 33 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 49 | 0.030 |
Why?
|
| Galanin | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 15 | 0.030 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2014 | 10 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2007 | 377 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 598 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 5 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 7 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2013 | 6 | 0.030 |
Why?
|
| ARNTL Transcription Factors | 1 | 2013 | 6 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 380 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 55 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2012 | 3 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 7 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2012 | 8 | 0.020 |
Why?
|
| Motor Neuron Disease | 1 | 1992 | 4 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 50 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2012 | 54 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2012 | 57 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 288 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2004 | 33 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 38 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 12 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 9 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 21 | 0.020 |
Why?
|
| Muscle Spasticity | 1 | 1992 | 4 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 1992 | 20 | 0.020 |
Why?
|
| Electrodes | 1 | 1992 | 13 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2012 | 43 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 144 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 144 | 0.020 |
Why?
|
| Income | 1 | 2012 | 67 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 177 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2012 | 39 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1991 | 2 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2011 | 2 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 30 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 168 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 107 | 0.020 |
Why?
|
| Pentetic Acid | 1 | 1990 | 1 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 1990 | 5 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1990 | 17 | 0.020 |
Why?
|
| Housing for the Elderly | 1 | 2010 | 6 | 0.020 |
Why?
|
| Pain Measurement | 1 | 1992 | 412 | 0.020 |
Why?
|
| Injections | 2 | 2005 | 42 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1993 | 271 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 180 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 314 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2008 | 2 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2005 | 203 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1988 | 54 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 27 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2007 | 85 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 5 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2007 | 37 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2006 | 29 | 0.020 |
Why?
|
| Fear | 1 | 2006 | 45 | 0.020 |
Why?
|
| Syndrome | 1 | 1986 | 68 | 0.020 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2005 | 5 | 0.010 |
Why?
|
| Education | 1 | 2005 | 31 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 94 | 0.010 |
Why?
|
| Salivation | 1 | 2005 | 1 | 0.010 |
Why?
|
| Parotid Gland | 1 | 2005 | 17 | 0.010 |
Why?
|
| West Nile virus | 1 | 2004 | 1 | 0.010 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2004 | 4 | 0.010 |
Why?
|
| Glutamate Decarboxylase | 1 | 2004 | 3 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 210 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 313 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 50 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2004 | 63 | 0.010 |
Why?
|
| Cyclins | 1 | 2000 | 5 | 0.010 |
Why?
|
| G1 Phase | 1 | 2000 | 16 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 80 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 22 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 67 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2000 | 43 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2001 | 537 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 194 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 2943 | 0.010 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 1992 | 5 | 0.010 |
Why?
|
| Pedigree | 1 | 1992 | 51 | 0.010 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1992 | 21 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 13 | 0.010 |
Why?
|
| Urinalysis | 1 | 1991 | 7 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1991 | 16 | 0.010 |
Why?
|
| Infant | 1 | 1991 | 483 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1991 | 569 | 0.000 |
Why?
|